)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
PolyPeptide Group
PolyPeptide Group (PPGN) investor relations material
PolyPeptide Group H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary13 Aug, 2026
Executive summary
Achieved 41.6% year-over-year revenue growth in H1 2026, reaching EUR 236.6 million, driven by strong demand in metabolic therapeutics and high utilization of new capacity, especially in Belgium.
EBITDA margin improved to 20.7% from 2.7% in H1 2025, reflecting operational leverage, efficiencies, and one-time favorable items.
Net income turned positive at EUR 9.1 million, reversing a loss of EUR 26.5 million in H1 2025.
Expanded phase III pipeline to 37 projects, representing about half of global phase III synthetic peptide drug development.
Samsung Biologics announced an all-cash public tender offer at CHF 44.31 per share, a 40% premium to undisturbed price, with board and anchor shareholder support.
Financial highlights
H1 2026 revenue reached EUR 236.6 million, up 41.6% year-over-year (43.7% at constant currency).
EBITDA rose to EUR 49.1 million (20.7% margin), up from EUR 4.4 million (2.7% margin) in H1 2025.
Operating result (EBIT) improved to EUR 22.0 million (9.3% margin) from a loss of EUR -13.7 million (-8.2% margin).
Net income reached EUR 9.1 million, reversing a loss of EUR -26.5 million in H1 2025.
Cash and cash equivalents at period end were EUR 59 million, with EUR 100 million drawn from a EUR 200 million revolving credit facility.
Outlook and guidance
Upgraded 2026 revenue growth guidance to 25%-30% (from 20%-25%) at constant currency and EBITDA margin to high teens.
CapEx guidance unchanged at 15%-20% of revenues.
Mid-term targets: double 2023 revenues by 2028 and EBITDA margin approaching 25%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from PolyPeptide Group
- 16% revenue growth and EBITDA margin at 12%, with strong outlook for 2026.PPGN
H2 2025 - H1 2025 revenue up 24%, guidance raised, and capacity expansions and financing enhanced.PPGNH1 2025
- EBITDA turned positive, revenue grew, and 2024 guidance was upgraded on strong demand.PPGNH1 2024
- 2024 delivered strong revenue and margin gains, with targets reaffirmed for doubling by 2028.PPGNH2 2024
Next PolyPeptide Group earnings date
H2 20269 Mar, 2027
PolyPeptide Group
Next PolyPeptide Group earnings date
H2 20269 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
PolyPeptide Group AG is a leading contract development and manufacturing organization (CDMO) specializing in the production of peptides and related molecules. The company provides services across the entire development spectrum, from initial peptide synthesis to commercial-scale manufacturing. PolyPeptide supports pharmaceutical and biotech companies with both proprietary and generic Good Manufacturing Practice (GMP)-grade peptides used in approved pharmaceutical products, drugs in clinical development, and in generic products. Additionally, it manufactures a variety of peptides used in cosmetic applications. The company is headquartered in Baar, Canton of Zug, Switzerland, and its shares are listed on the stock exchange.